ArticleJournal of surgical oncology2026
Surgical Management of Recurrent Retroperitoneal Sarcomas: Experience From a High-Volume Sarcoma Centre: Recurrent Retroperitoneal Sarcomas: Outcomes of Multiple Recurrences.
Article in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRetroperitoneal sarcoma (RPS) is a rare and complex malignancy, requiring specialized multidisciplinary care. While a significant progress has been made in managing a primary RPS, there is a limited literature on the outcomes of recurrent RPS (RecRPS). This study evaluates the oncological outcomes of RecRPS at a leading sarcoma referral center in India.
methodsA retrospective analysis was performed for patients with RecRPS who underwent surgery between January 2011 and December 2024. Clinical outcomes were analyzed using Kaplan-Meier method and compared using log-rank test. Extended Cox regression models were used to account for intra-individual correlation, in cases of multiple recurrence. Prentice, William and Peterson model (PWP) CP model (total time) and PWP Gap time (PWP-GT) models were employed to estimate predictors of multiple recurrences.
resultsOut of 285 patients with primary RPS, 160 (56.1%) underwent surgery for a recurrent disease. The median overall survival (OS) was 137.1 months for the entire cohort and 41.92 months in RecRPS. The median OS of patients with 1st recurrence was 38.97 months. For subsequent recurrences, the median OS were 74.94 months (2nd recurrence), 57.4 months (3rd recurrence) and 54.2 months (4th recurrence), respectively. The various clinicopathological parameter associated with multiple recurrences were R+resection or resection with unknown margins, dedifferentiated liposarcoma and leiomyosarcoma, as histopatholologic subtypes; histologic organ invasion (HOI) of the small bowel and vessels, requirement of adjuvant and neoadjuvant therapy, disease progression on neoadjuvant chemotherapy and grade IIIb and IV complications.
conclusionWhile the best chance of cure is at the primary presentation, some patients may experience prolonged disease control even with multiple recurrence, if treated optimally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.